百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301015 百洋医药

已收盘 11-20 15:00:00

{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":28.33,"timestamp":1732086228000,"preClose":28.04,"halted":0,"volume":2575237,"delay":0,"floatShares":526000000,"shares":526000000,"eps":1.5281,"marketStatus":"已收盘","marketStatusCode":5,"change":0.29,"latestTime":"11-20 15:00:00","open":28,"high":28.6,"low":27.82,"amount":72849400,"amplitude":0.0278,"askPrice":28.33,"askSize":14,"bidPrice":28.32,"bidSize":8,"shortable":0,"etf":0,"ttmEps":1.5281,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732152600000},"adr":0,"adjPreClose":28.04,"symbolType":"stock","openAndCloseTimeList":[[1732066200000,1732073400000],[1732078800000,1732086000000]],"highLimit":30.84,"lowLimit":25.24,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525613491,"pbRate":6.67,"roa":"--","roe":"22.95%","epsLYR":1.25,"committee":0.422939,"marketValue":14891000000,"floatMarketCap":14891000000,"peRate":18.539362,"changeRate":0.0103,"turnoverRate":0.0049,"status":0},"requestUrl":"/m/hq/s/301015/wiki","defaultTab":"wiki","newsList":[{"id":"2483003806","title":"百洋医药：子公司与北京华昊中天签订市场推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483003806","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483003806?lang=zh_cn&edition=full","pubTime":"2024-11-14 22:06","pubTimestamp":1731593178,"startTime":"0","endTime":"0","summary":"中国财富通11月14日 - 百洋医药（301015）公告称，近日，公司全资子公司百洋智合与北京华昊中天签订《市场推广服务协议》，约定北京华昊中天指定百洋智合在区域内进行指定产品（优替德隆注射液，商品名：优替帝）的独家市场推广服务。同日，百洋智合与北京华昊中天、成都华昊中天签订《市场推广服务协议补充协议》，各方同意授权百洋智合按照协议约定在区域内独占和排他地推广指定产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=B8FHv8ByeRs%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2483840518","title":"百洋医药最新公告：全资子公司签订市场推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483840518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483840518?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:48","pubTimestamp":1731574122,"startTime":"0","endTime":"0","summary":"百洋医药公告，近日，公司全资子公司北京百洋智合医学成果转化服务有限公司（简称“百洋智合”）与北京华昊中天生物医药股份有限公司（简称“北京华昊中天”）签订了《市场推广服务协议》，约定北京华昊中天指定百洋智合在区域内进行指定产品（优替德隆注射液，商品名：优替帝）的独家市场推广服务。同日，百洋智合与北京华昊中天、成都华昊中天药业有限公司签订了《市场推广服务协议补充协议》，各方同意授权百洋智合按照协议约定在区域内独占和排他地推广指定产品。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400026930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2483784239","title":"11月14日百洋医药跌5.03%，安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483784239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483784239?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:20","pubTimestamp":1731572431,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日百洋医药跌5.03%，收盘报29.05元，换手率0.91%，成交量4.79万手，成交额1.43亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共23家，其中持有数量最多的公募基金为安信医药健康股票A。安信医药健康股票A目前规模为14.92亿元，最新净值1.0129，较上一交易日下跌1.75%，近一年下跌17.23%。安信医药健康股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400026065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2483454841","title":"百洋医药(301015.SZ)子公司与北京华昊中天签订市场推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483454841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483454841?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:58","pubTimestamp":1731571082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百洋医药 公告，公司全资子公司北京百洋智合医学成果转化服务有限公司与北京华昊中天生物医药股份有限公司签订了《市场推广服务协议》，约定北京华昊中天指定百洋智合在区域内进行指定产品的独家市场推广服务。同日，百洋智合与北京华昊中天、成都华昊中天药业有限公司签订了《市场推广服务协议补充协议》，各方同意授权百洋智合按照协议约定在区域内独占和排他地推广指定产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2483464478","title":"百洋医药：签订独家市场推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483464478","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483464478?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:46","pubTimestamp":1731570373,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2482721005","title":"11月12日百洋医药涨8.22%，安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482721005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482721005?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:11","pubTimestamp":1731399107,"startTime":"0","endTime":"0","summary":"证券之星消息，11月12日百洋医药涨8.22%，收盘报31.6元，换手率1.92%，成交量10.12万手，成交额3.11亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共23家，其中持有数量最多的公募基金为安信医药健康股票A。安信医药健康股票A目前规模为14.92亿元，最新净值1.0146，较上一交易日上涨1.35%，近一年下跌17.49%。安信医药健康股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200025453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2482724838","title":"百洋医药涨8.22%，中泰证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2482724838","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482724838?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:11","pubTimestamp":1731399102,"startTime":"0","endTime":"0","summary":"今日百洋医药（301015）涨8.22%，收盘报31.6元。2024年10月28日，中泰证券研究员祝嘉琦,孙宇瑶发布了对百洋医药的研报《业绩符合预期，品牌运营稳健发展》，该研报对百洋医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为78.7%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为天风证券的杨松。百洋医药（301015）个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200025450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","600918"],"gpt_icon":0},{"id":"2481317080","title":"百洋医药(301015.SZ)子公司拟认购Zap Medical System, Ltd.E系列优先股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481317080","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481317080?lang=zh_cn&edition=full","pubTime":"2024-11-08 21:13","pubTimestamp":1731071622,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百洋医药 公告，公司全资子公司河北百洋诚达医药有限公司、百洋健康产业国际商贸有限公司拟与标的公司Zap Medical System, Ltd.签订《首轮E系列优先股认购协议》，参与认购标的公司发行的E系列优先股。公告显示，Zap Medical System, Ltd.核心产品为头颈部X射线放射外科治疗系统，是一款专为优化颅内和颈部实体恶性肿瘤、病变治疗而设计的放射外科设备，已于2023年6月20日正式在中国获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2481124910","title":"百洋医药最新公告：拟成为产品“ZAP-X®系统”及配件“兆伏闪烁探测器”独家经销商","url":"https://stock-news.laohu8.com/highlight/detail?id=2481124910","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481124910?lang=zh_cn&edition=full","pubTime":"2024-11-08 18:41","pubTimestamp":1731062468,"startTime":"0","endTime":"0","summary":"百洋医药公告，全资子公司河北百洋诚达医药有限公司、百洋健康产业国际商贸有限公司拟与Zap Medical System, Ltd.签订协议，参与认购标的公司发行的E系列优先股。同日公告，公司及全资子公司百洋健康产业国际商贸有限公司拟与ZAP Surgical Systems, Inc.签订协议，成为产品“ZAP-X®系统”及配件“兆伏闪烁探测器”在协议区域（中国包括香港和澳门）内的独家经销商。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800033499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2481076121","title":"百洋医药(301015.SZ)与ZAP签署分销协议 涉及一款放射外科设备","url":"https://stock-news.laohu8.com/highlight/detail?id=2481076121","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481076121?lang=zh_cn&edition=full","pubTime":"2024-11-08 18:30","pubTimestamp":1731061853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百洋医药 公告，公司及全资子公司百洋健康产业国际商贸有限公司拟与ZAP Surgical Systems, Inc.签订《国际分销协议》，约定ZAP指定百洋为其产品“ZAP-X系统”及配件“兆伏闪烁探测器”在协议区域内的独家经销商。据公告所示，本次双方合作的ZAP-X是ZAP的核心产品头颈部X射线放射外科治疗系统，是一款专为优化颅内和颈部实体恶性肿瘤、病变治疗而设计的放射外科设备。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301015","BK0250"],"gpt_icon":0},{"id":"2481147374","title":"华福证券：给予百洋医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481147374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481147374?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:49","pubTimestamp":1731055751,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司王艳,黄冠群近期对百洋医药进行研究并发布了研究报告《业绩符合预期，制药并表提供新增长动能》，本报告对百洋医药给出买入评级，当前股价为28.35元。24年7月百洋制药纳入合并报表范围，根据收购公告，百洋制药业绩承诺24-26年扣非归母净利润分别为不低于1.4亿、1.7亿、2.2亿元。最新盈利预测明细如下：该股最近90天内共有11家机构给出评级，买入评级10家，增持评级1家；过去90天内机构目标均价为27.03。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800027317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301015"],"gpt_icon":0},{"id":"2480741533","title":"信达证券：给予百洋医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480741533","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480741533?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:28","pubTimestamp":1730712515,"startTime":"0","endTime":"0","summary":"信达证券股份有限公司唐爱金,章钟涛近期对百洋医药进行研究并发布了研究报告《公司首次覆盖报告：品牌运营“内生增长+外延扩张”双驱动，公司有望业绩&估值双提升》，本报告对百洋医药 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20241104/c663147647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["601059","301015"],"gpt_icon":0},{"id":"2480079189","title":"11月1日百洋医药涨5.29%，安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480079189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480079189?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:32","pubTimestamp":1730449952,"startTime":"0","endTime":"0","summary":"证券之星消息，11月1日百洋医药涨5.29%，收盘报28.68元，换手率1.24%，成交量6.5万手，成交额1.83亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共23家，其中持有数量最多的公募基金为安信医药健康股票A。安信医药健康股票A目前规模为14.92亿元，最新净值0.9683，较上一交易日下跌1.24%，近一年下跌17.88%。安信医药健康股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100029985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2480079985","title":"百洋医药涨5.29%，中泰证券四日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480079985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480079985?lang=zh_cn&edition=full","pubTime":"2024-11-01 16:32","pubTimestamp":1730449948,"startTime":"0","endTime":"0","summary":"今日百洋医药（301015）涨5.29%，收盘报28.68元。2024年10月28日，中泰证券研究员祝嘉琦,孙宇瑶发布了对百洋医药的研报《业绩符合预期，品牌运营稳健发展》，该研报对百洋医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为78.7%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为天风证券的杨松。百洋医药（301015）个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100029984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600918","301015"],"gpt_icon":0},{"id":"2480025318","title":"百洋医药旗下同昕生物自主研发的鼻咽癌辅助诊断试剂盒获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2480025318","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480025318?lang=zh_cn&edition=full","pubTime":"2024-11-01 13:58","pubTimestamp":1730440719,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4108","EB","BK0250","BK4077","301015"],"gpt_icon":0},{"id":"2479773797","title":"财信证券：给予百洋医药买入评级，目标价位40.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479773797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479773797?lang=zh_cn&edition=full","pubTime":"2024-10-31 09:02","pubTimestamp":1730336547,"startTime":"0","endTime":"0","summary":"财信证券股份有限公司吴号近期对百洋医药进行研究并发布了研究报告《品牌运营业务增长较快，盈利水平持续提升》，本报告对百洋医药给出买入评级，认为其目标价位为40.80元，当前股价为27.39元，预期上涨幅度为48.96%。最新盈利预测明细如下：该股最近90天内共有10家机构给出评级，买入评级9家，增持评级1家；过去90天内机构目标均价为27.03。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100012243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301015"],"gpt_icon":0},{"id":"2479214114","title":"华源证券：给予百洋医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479214114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479214114?lang=zh_cn&edition=full","pubTime":"2024-10-30 11:57","pubTimestamp":1730260636,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯近期对百洋医药进行研究并发布了研究报告《品牌运营业务盈利能力持续提升》，本报告对百洋医药给出买入评级，当前股价为27.4元。百洋医药为国内领先的医药商业化平台，具备优异的品牌打造能力及全渠道运营能力，已成功打造出多个收入亿级及十亿级单品，商业化能力得到充分验证，目前正在加速布局创新药械，随着相关产品陆续进入收获期，长期成长天花板有望打开，维持公司“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000019720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301015"],"gpt_icon":0},{"id":"2479850292","title":"开源证券：给予百洋医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479850292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479850292?lang=zh_cn&edition=full","pubTime":"2024-10-29 22:01","pubTimestamp":1730210490,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,巢舒然近期对百洋医药进行研究并发布了研究报告《公司信息更新报告：2024Q3经营业绩稳健增长，品牌运营业务稳健》，本报告对百洋医药给出买入评级，当前股价为27.91元。最新盈利预测明细如下：该股最近90天内共有10家机构给出评级，买入评级9家，增持评级1家；过去90天内机构目标均价为27.03。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900041417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","301015"],"gpt_icon":0},{"id":"2479890421","title":"10月29日百洋医药跌5.68%，安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479890421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479890421?lang=zh_cn&edition=full","pubTime":"2024-10-29 16:22","pubTimestamp":1730190171,"startTime":"0","endTime":"0","summary":"证券之星消息，10月29日百洋医药跌5.68%，收盘报27.91元，换手率0.92%，成交量4.83万手，成交额1.38亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共23家，其中持有数量最多的公募基金为安信医药健康股票A。安信医药健康股票A目前规模为14.92亿元，最新净值1.0195，较上一交易日上涨1.42%，近一年下跌12.01%。安信医药健康股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900027623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"gpt_icon":0},{"id":"2478618497","title":"百洋医药（301015）2024年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478618497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478618497?lang=zh_cn&edition=full","pubTime":"2024-10-27 11:01","pubTimestamp":1729998094,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百洋医药发布2024年三季报。截至本报告期末，公司营业总收入61.44亿元，同比上升2.65%，归母净利润6.41亿元，同比上升17.42%。按单季度数据看，第三季度营业总收入25.49亿元，同比上升8.46%，第三季度归母净利润2.72亿元，同比上升11.86%。本报告期百洋医药盈利能力上升，毛利率同比增幅12.92%，净利率同比增幅53.05%。持有百洋医药最多的基金为安信医药健康股票A，目前规模为14.92亿元，最新净值1.0052，较上一交易日上涨1.57%，近一年下跌7.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700011471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","stockEarnings":[{"period":"1week","weight":-0.1127},{"period":"1month","weight":0.0094},{"period":"3month","weight":0.3164},{"period":"6month","weight":-0.1134},{"period":"1year","weight":-0.2471},{"period":"ytd","weight":-0.1984}],"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","perCapita":"57519股","boardName":"批发业","registeredCapital":"52561万元","compareEarnings":[{"period":"1week","weight":-0.0222},{"period":"1month","weight":0.0259},{"period":"3month","weight":0.1713},{"period":"6month","weight":0.0737},{"period":"1year","weight":0.0905},{"period":"ytd","weight":0.1247}],"survey":"　　青岛百洋医药股份有限公司是专业的医药产品商业化平台，主营业务是为医药产品生产企业提供商业化整体解决方案，包括提供医药产品的品牌运营、批发配送及零售，致力于成为连接医药产品和下游消费者的纽带，为品牌医药生产企业提供产品营销的综合解决方案。","serverTime":1732103317623,"listedPrice":7.64,"stockholders":"9138人(较上一季度减少1.85%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}